Identification

Name
Beclomethasone dipropionate
Accession Number
DB00394  (APRD00564, DB11897)
Type
Small Molecule
Groups
Approved, Investigational
Description

Beclomethasone dipropionate is a prodrug of the free form, beclomethasone (beclomethasone-17-monopropionate). An anti-inflammatory, synthetic corticosteroid, it is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma and allergic rhinitis (seasonal and perennial). Beclometasone dipropionate is also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease. It is marketed under several brand names such as Qnasl (US) and Rivanase AQ (Canada).

Structure
Thumb
Synonyms
  • (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
  • 9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
  • 9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate
  • beclometasone 17,21-dipropionate
  • Beclometasone dipropionate
External IDs
SCH 18020W / SCH 8020W / SCH-18020W / SGX-201 / SGX-202 / SGX-203
Product Ingredients
IngredientUNIICASInChI Key
Beclomethasone dipropionate monohydrate4H7L9AI22I77011-63-3QHQJZIXSVLFOHD-LYRZEVDOSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-beclomethasone Dipropionate Inhaler 50mcg/mdAerosol, metered50 mcgRespiratory (inhalation)Altimed Pharma Inc.1992-12-312005-05-27Canada
Beclodisk - Pwr Inh 100mcg/blisterPowder100 mcgRespiratory (inhalation)Glaxo Wellcome1997-09-032000-05-24Canada
Beclodisk - Pwr Inh 200mcg/blisterPowder200 mcgRespiratory (inhalation)Glaxo Wellcome1997-06-112000-05-24Canada
Beclodisk Pwr 100mcg/blisterPowder100 mcgRespiratory (inhalation)Glaxo Canada Inc1989-12-311998-07-30Canada
Beclodisk Pwr 200mcg/blisterPowder200 mcgRespiratory (inhalation)Glaxo Canada Inc1989-12-311998-07-30Canada
Becloforte 250mcg/aemAerosol, metered250 mcgRespiratory (inhalation)Glaxo Canada Inc1988-12-311998-07-30Canada
Becloforte Inhaler - Aem Inh 250mcg/aemAerosol, metered250 mcgRespiratory (inhalation)Glaxo Wellcome1997-02-112000-05-24Canada
Beclomethasone Aqueous Nasal Spray 50mcg/metered DoseAerosol, metered; Suspension50 mcgNasalPrempharm Inc1997-01-052005-08-05Canada
Beclomethasone Dipropionate Nas-spr 50mcg/aemAerosol, metered50 mcgNasalKenral Inc.1992-12-311997-08-11Canada
Beclomethasone Dipropionate Nasal InhalerAerosol, metered50 mcgNasalPharmaco Canada Inc.1994-12-312001-07-18Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-beclomethasone Nasal SpraySuspension50 mcgNasalApotex Corporation1998-10-07Not applicableCanada
International/Other Brands
Aerobec (Teva) / Aldecin (Schering-Plough) / Anceron / Andion / Beclacin (Mayado Seiyaku) / Becloforte (GlaxoSmithKline) / Beclomet (Orion) / Beclorhinol (Chiesi) / Becloval / Beclovent (GlaxoSmithKline) / Becodisks (GlaxoSmithKline) / Beconase (GlaxoSmithKline) / Beconasol / Becotide (GlaxoSmithKline) / Clenil-A / Entyderma / Inalone (GlaxoSmithKline) / Korbutone / orBec (DOR BioPharma, Inc.) / Rino-Clenil (Chiesi) / Rivanase / Sanasthmax (Chiesi) / Sanasthmyl / Vancenase / Vanceril
Categories
UNII
5B307S63B2
CAS number
5534-09-8
Weight
Average: 521.042
Monoisotopic: 520.222781245
Chemical Formula
C28H37ClO7
InChI Key
KUVIULQEHSCUHY-XYWKZLDCSA-N
InChI
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
IUPAC Name
2-[(1R,2S,10S,11S,13S,14R,15S,17S)-1-chloro-17-hydroxy-2,13,15-trimethyl-5-oxo-14-(propanoyloxy)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate
SMILES

Pharmacology

Indication

Used in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.

Structured Indications
Pharmacodynamics

Beclometasone, a synthetic halogenated glucocorticoid with antiinflammatory and vasoconstrictive effects, is used for treating steroid-dependent asthma, allergic or nonallergic rhinitis, or recurrent nasal polyps.

Mechanism of action

Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

For the investigated use in the treatment of GvHD or Crohn's, beclometasone acts by binding to interleukin-13 to inhibit cytokines, which in turn inhibits inflammatory chemicals downstream.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Mean peak plasma concentration was 88pg/ml at 0.5 hour.

Volume of distribution

The steady state volume of distribution for beclomethasone dipropionate is 20 L, and for it's active metabolite, beclomethasone-17-monopropionate, it is much larger at 424 L.

Protein binding

87% to albumin and transcortin

Metabolism

Metabolism mediated via esterase enzymes that are found in most tissues. Undergoes rapid and extensive conversion to beclomenthasone-17-monopropionate (17-BMP) during absorption

Route of elimination

Irrespective of the route of administration (injection, oral or inhalation), BDP and its metabolites are mainly excreted in the feces. Less than 10% of the drug and its metabolites are excreted in the urine.

Half life

2.8 hours

Clearance

High plasma clearance after intravenous administration (150 and 120 L/hour).

Toxicity

The acute toxicity of beclometasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclometasone dipropionate over a long period could lead to adrenal suppression.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Beclomethasone dipropionate.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Beclomethasone dipropionate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Beclomethasone dipropionate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Beclomethasone dipropionate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Beclomethasone dipropionate.Approved, Withdrawn
AldesleukinBeclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Beclomethasone dipropionate.Experimental
AloglutamolThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Beclomethasone dipropionate.Experimental
AluminiumThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Beclomethasone dipropionate.Approved
AmiodaroneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BBeclomethasone dipropionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Beclomethasone dipropionate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Beclomethasone dipropionate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Beclomethasone dipropionate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Beclomethasone dipropionate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Beclomethasone dipropionate.Approved, Investigational
AprepitantThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Beclomethasone dipropionate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Beclomethasone dipropionate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Beclomethasone dipropionate.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Beclomethasone dipropionate.Experimental
BendroflumethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Beclomethasone dipropionate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Beclomethasone dipropionate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Beclomethasone dipropionate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Beclomethasone dipropionate.Experimental
Bismuth SubcitrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Beclomethasone dipropionate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Beclomethasone dipropionate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Beclomethasone dipropionate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Beclomethasone dipropionate.Experimental
BumetanideBeclomethasone dipropionate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Beclomethasone dipropionate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideBeclomethasone dipropionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Beclomethasone dipropionate.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Beclomethasone dipropionate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Beclomethasone dipropionate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Beclomethasone dipropionate.Approved, Investigational
CeritinibBeclomethasone dipropionate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Beclomethasone dipropionate.Approved, Vet Approved
ChlorothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneBeclomethasone dipropionate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Beclomethasone dipropionate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Beclomethasone dipropionate.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Beclomethasone dipropionate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Beclomethasone dipropionate.Investigational
CyclopenthiazideBeclomethasone dipropionate may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Beclomethasone dipropionate.Investigational
DaidzeinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Beclomethasone dipropionate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Beclomethasone dipropionate.Approved, Vet Approved
DienestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Beclomethasone dipropionate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone dipropionate.Approved
DihydrotestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Beclomethasone dipropionate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Beclomethasone dipropionate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Beclomethasone dipropionate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Beclomethasone dipropionate.Approved
EquolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrone.Approved
Etacrynic acidBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Beclomethasone dipropionate.Experimental
Ethinyl EstradiolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Beclomethasone dipropionate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Beclomethasone dipropionate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Beclomethasone dipropionate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Beclomethasone dipropionate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Beclomethasone dipropionate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Beclomethasone dipropionate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Beclomethasone dipropionate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Beclomethasone dipropionate.Approved
FenthionThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Beclomethasone dipropionate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Beclomethasone dipropionate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Beclomethasone dipropionate.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Beclomethasone dipropionate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Beclomethasone dipropionate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Beclomethasone dipropionate.Experimental
FluoxymesteroneBeclomethasone dipropionate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Beclomethasone dipropionate.Approved, Investigational
FosaprepitantThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Fosphenytoin.Approved
FurosemideBeclomethasone dipropionate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Beclomethasone dipropionate may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Beclomethasone dipropionate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Beclomethasone dipropionate.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Beclomethasone dipropionate.Experimental
HexestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Beclomethasone dipropionate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
HydrochlorothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Beclomethasone dipropionate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Beclomethasone dipropionate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Beclomethasone dipropionate.Approved
IdelalisibThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Beclomethasone dipropionate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Beclomethasone dipropionate.Approved
IndapamideBeclomethasone dipropionate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Beclomethasone dipropionate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Beclomethasone dipropionate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Beclomethasone dipropionate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Beclomethasone dipropionate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Beclomethasone dipropionate.Withdrawn
ItraconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Beclomethasone dipropionate.Experimental
KetoconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Beclomethasone dipropionate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Beclomethasone dipropionate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Beclomethasone dipropionate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Beclomethasone dipropionate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Beclomethasone dipropionate.Experimental
LopinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Beclomethasone dipropionate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Beclomethasone dipropionate.Approved
LumacaftorThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Beclomethasone dipropionate.Approved, Investigational
MagaldrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Beclomethasone dipropionate.Approved
Magnesium silicateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Beclomethasone dipropionate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone dipropionate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Beclomethasone dipropionate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Beclomethasone dipropionate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beclomethasone dipropionate.Approved
MesteroloneBeclomethasone dipropionate may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Beclomethasone dipropionate.Withdrawn
MethallenestrilThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Metoclopramide.Approved, Investigational
MetolazoneBeclomethasone dipropionate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Minaprine.Approved
MitotaneThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Beclomethasone dipropionate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Beclomethasone dipropionate.Experimental
MoxestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Beclomethasone dipropionate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Beclomethasone dipropionate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Beclomethasone dipropionate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Beclomethasone dipropionate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Beclomethasone dipropionate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nalidixic Acid.Approved
NandroloneBeclomethasone dipropionate may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Beclomethasone dipropionate.Approved, Vet Approved
NefazodoneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Beclomethasone dipropionate.Approved
NevirapineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Beclomethasone dipropionate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Beclomethasone dipropionate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Beclomethasone dipropionate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Beclomethasone dipropionate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Beclomethasone dipropionate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone dipropionate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Beclomethasone dipropionate.Vet Approved
OxandroloneBeclomethasone dipropionate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Beclomethasone dipropionate.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Oxolinic acid.Experimental
OxymetholoneBeclomethasone dipropionate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Beclomethasone dipropionate.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Beclomethasone dipropionate.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Beclomethasone dipropionate.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Beclomethasone dipropionate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Beclomethasone dipropionate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
PhenytoinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Beclomethasone dipropionate.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pipemidic acid.Experimental
PiretanideBeclomethasone dipropionate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Beclomethasone dipropionate.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Beclomethasone dipropionate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Beclomethasone dipropionate.Experimental
Polyestradiol phosphateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideBeclomethasone dipropionate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Beclomethasone dipropionate.Experimental
PrimidoneThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Beclomethasone dipropionate.Experimental
PromestrieneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Beclomethasone dipropionate.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Beclomethasone dipropionate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Beclomethasone dipropionate.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Beclomethasone dipropionate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Quinestrol.Approved
QuinethazoneBeclomethasone dipropionate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone dipropionate.Experimental, Investigational
RifabutinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Beclomethasone dipropionate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Beclomethasone dipropionate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Beclomethasone dipropionate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Beclomethasone dipropionate.Approved
SaquinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Beclomethasone dipropionate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Beclomethasone dipropionate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Beclomethasone dipropionate.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Beclomethasone dipropionate.Investigational
St. John's WortThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololBeclomethasone dipropionate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Beclomethasone dipropionate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Beclomethasone dipropionate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Beclomethasone dipropionate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Beclomethasone dipropionate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Beclomethasone dipropionate.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Beclomethasone dipropionate.Withdrawn
TelithromycinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Beclomethasone dipropionate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Beclomethasone dipropionate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Beclomethasone dipropionate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Beclomethasone dipropionate.Approved
TestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Beclomethasone dipropionate.Approved
TiboloneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Beclomethasone dipropionate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Beclomethasone dipropionate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Beclomethasone dipropionate.Approved
TorasemideBeclomethasone dipropionate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Beclomethasone dipropionate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Beclomethasone dipropionate.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trichlorfon.Vet Approved
TrichlormethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Beclomethasone dipropionate.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Beclomethasone dipropionate.Investigational, Withdrawn
VoriconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinBeclomethasone dipropionate may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Beclomethasone dipropionate.Approved
ZeranolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Beclomethasone dipropionate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Beclomethasone dipropionate.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Zoster vaccine.Approved
Food Interactions
  • No food effects were found when given with beclomethasone dipropionate.

References

Synthesis Reference

Taub, D., Wendler, N.L. and Slates, H.L.; US.Patent 3,345,387; October 3, 1967; assigned to Merck & Co., Inc.

General References
  1. Willey RF, Milne LJ, Crompton GK, Grant IW: Beclomethasone dipropionate aerosol and oropharyngeal candidiasis. Br J Dis Chest. 1976 Jan;70(1):32-8. [PubMed:1259918]
  2. Salzman GA, Pyszczynski DR: Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J Allergy Clin Immunol. 1988 Feb;81(2):424-8. [PubMed:3339197]
  3. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, Kohno S: Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol. 2003 Jun;90(6):646-51. [PubMed:12839324]
  4. Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M: Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study. Biomed Pharmacother. 2007 Jul;61(6):370-6. Epub 2007 Mar 12. [PubMed:17399941]
  5. McDonald GB: Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation. Expert Opin Investig Drugs. 2007 Oct;16(10):1709-24. [PubMed:17922633]
  6. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB: A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007 May 15;109(10):4557-63. Epub 2007 Jan 23. [PubMed:17244684]
  7. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, Diez-Campelo M, Ocio E, Perez-Persona E, Lopez-Villar O, Vazquez L, Caballero D, San Miguel JF: Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant. 2006 Sep;12(9):936-41. [PubMed:16920559]
External Links
Human Metabolome Database
HMDB14538
KEGG Drug
D07495
KEGG Compound
C07813
PubChem Compound
21700
PubChem Substance
46509195
ChemSpider
20396
ChEBI
3002
ChEMBL
CHEMBL1200500
Therapeutic Targets Database
DAP000416
PharmGKB
PA448547
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Beclometasone_dipropionate
ATC Codes
R03BA01 — BeclometasoneR03AK08 — Formoterol and beclometasoneA07EA07 — BeclometasoneD07CC04 — Beclometasone and antibioticsR01AD01 — BeclometasoneD07AC15 — Beclometasone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (255 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAllergic Rhinitis (AR)1
1CompletedNot AvailableOesophagitis, Eosinophilic1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
1, 2CompletedSupportive CareCancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Neuroblastomas / Renal Cancers / Testicular germ cell tumour1
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Disease, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentAsthma Bronchial / Bronchial Hyperresponsiveness1
2CompletedTreatmentHayfever / Seasonal Allergic Rhinitis (SAR)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2CompletedTreatmentRhinitis, Allergic, Seasonal1
2Not Yet RecruitingOtherAsthma Bronchial1
2RecruitingTreatmentAsthma Bronchial1
2RecruitingTreatmentChronic Lung Disease of Prematurity1
2TerminatedTreatmentChronic Gastrointestinal Graft vs Host Disease1
2Unknown StatusTreatmentPolyps, Nasal1
2WithdrawnTreatmentAsthma Bronchial1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
2, 3CompletedTreatmentAsthma Bronchial1
2, 3SuspendedTreatmentFolliculitis1
3CompletedNot AvailableChronic Lung Disease of Prematurity / Chronic Lung Diseases / Hyaline Membrane Disease1
3CompletedSupportive CareGraft Versus Host Disease (GVHD)1
3CompletedTreatmentAcute Rhinosinusitis1
3CompletedTreatmentAllergic Rhinitis (AR)2
3CompletedTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
3CompletedTreatmentAsthma Bronchial13
3CompletedTreatmentAsthma Bronchial / Chronic Lung Diseases1
3CompletedTreatmentBronchial Asthma1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentGastrointestinal Graft-Versus-Host Disease / Graft Versus Host Disease (GVHD)1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentPersistent Asthma1
3CompletedTreatmentPollen Allergy / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentRespiratory Tract Diseases / Wheezing1
3CompletedTreatmentRhinitis, Allergic, Perennial3
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR) / Severe Acute Respiratory Syndrome1
3TerminatedTreatmentAcute Gastrointestinal Graft vs Host Disease1
4CompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
4CompletedPreventionBronchial Spasm / Respiratory Sounds / Respiratory Tract Infections (RTI)1
4CompletedPreventionSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4CompletedTreatmentAsthma Bronchial5
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4Enrolling by InvitationTreatmentAsthma Bronchial1
4Not Yet RecruitingPreventionAnesthesia, Endotracheal1
4RecruitingTreatmentAllergic Rhinitis (AR)1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentPulmonary Disease,Chronic Obstructive1
4TerminatedTreatmentAsthma Bronchial1
4TerminatedTreatmentDyspnea / Wheezing1
4Unknown StatusDiagnosticChronic Obstructive Pulmonary Disease (COPD) / Emphysema / Small Airway Disease1
4WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4WithdrawnTreatmentWheezing1
Not AvailableActive Not RecruitingBasic ScienceAsthma Bronchial1
Not AvailableActive Not RecruitingTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAllergic Rhinitis (AR)1
Not AvailableCompletedNot AvailableAsthma Bronchial5
Not AvailableCompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailablePerennial Allergic Rhinitis (PAR)1
Not AvailableCompletedSupportive CareGraft Versus Host Disease (GVHD)1
Not AvailableCompletedTreatmentIntraocular Pressure1
Not AvailableRecruitingHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableTerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusNot AvailableAllergic Rhinitis (AR) / Asthma Bronchial1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Schering corp sub schering plough corp
  • Schering corp
Packagers
Dosage forms
FormRouteStrength
PowderRespiratory (inhalation)100 mcg
PowderRespiratory (inhalation)200 mcg
Aerosol, meteredRespiratory (inhalation)250 mcg
CapsuleRespiratory (inhalation)100 mcg
CapsuleRespiratory (inhalation)200 mcg
Spray, suspensionNasal42 ug/1
Aerosol, meteredNasal50 mcg
Aerosol, metered; suspensionNasal50 mcg
SuspensionNasal50 mcg
CreamTopical0.025 %
CreamTopical.025 %
LotionTopical.025 %
LotionTopical0.025 %
Aerosol, meteredNasal40 ug/1
Aerosol, meteredNasal80 ug/1
Aerosol, meteredRespiratory (inhalation)100 mcg
Aerosol, meteredRespiratory (inhalation)40 ug/1
Aerosol, meteredRespiratory (inhalation)50 mcg
Aerosol, meteredRespiratory (inhalation)80 ug/1
SprayNasal50 mcg
Prices
Unit descriptionCostUnit
Beconase AQ 42 mcg/spray Suspension 25 gm Inhaler149.32USD inhaler
Beclomethasone dipro powder107.1USD g
Qvar 80 mcg/act Aerosol 7.3 gm Inhaler105.64USD inhaler
Qvar 40 mcg/act Aerosol 7.3 gm Inhaler87.5USD inhaler
Qvar 80 mcg inhaler19.05USD g
Qvar 40 mcg inhaler15.12USD g
Propaderm 250 mcg/g Cream0.46USD g
Qvar Cfc-Free 100 mcg/dose Metered Dose Aerosol0.33USD dose
Qvar Cfc-Free 50 mcg/dose Metered Dose Aerosol0.16USD dose
Apo-Beclomethasone 50 mcg/dose Metered Dose Spray0.06USD dose
Mylan-Beclo Aq. 50 mcg/dose Metered Dose Spray0.06USD dose
Nu-Beclomethasone 50 mcg/dose Metered Dose Spray0.06USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5776432No1995-07-072015-07-07Us
US6446627No1997-12-182017-12-18Us
US7780038No2007-01-242027-01-24Us
US9463289No2011-05-182031-05-18Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)117-120 °CNot Available
water solubility49.39 mg/LNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00208 mg/mLALOGPS
logP3.69ALOGPS
logP4.43ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)13.85ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.97 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity134.79 m3·mol-1ChemAxon
Polarizability54.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9904
Blood Brain Barrier+0.9851
Caco-2 permeable+0.5698
P-glycoprotein substrateSubstrate0.7529
P-glycoprotein inhibitor IInhibitor0.5986
P-glycoprotein inhibitor IINon-inhibitor0.7488
Renal organic cation transporterNon-inhibitor0.7907
CYP450 2C9 substrateNon-substrate0.8634
CYP450 2D6 substrateNon-substrate0.9174
CYP450 3A4 substrateSubstrate0.784
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.7875
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8577
Ames testNon AMES toxic0.938
CarcinogenicityNon-carcinogens0.914
BiodegradationNot ready biodegradable0.9932
Rat acute toxicity2.1115 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9456
hERG inhibition (predictor II)Non-inhibitor0.6054
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0536-0000390000-d1146b326a2bf27937e3
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0489240000-9581961e5dddfb7a403f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0h71-3892000000-454fb634c4339a1ebfe0

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters
show 7 more
Substituents
Progestogin-skeleton / Steroid ester / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / 9-halo-steroid / Halo-steroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
propanoate ester, enone, 11beta-hydroxy steroid, glucocorticoid, steroid ester, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid, corticosteroid (CHEBI:3002)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Saklatvala J: Glucocorticoids: do we know how they work? Arthritis Res. 2002;4(3):146-50. Epub 2002 Jan 21. [PubMed:12010562]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]
  3. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005 Sep 15;172(6):704-12. Epub 2005 Apr 28. [PubMed:15860753]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Landyshev IuS, Grigorenko AA, Marikhina NS, Molochnaia SV: [A comparative assessment of the effect of different methods of glucocorticosteroid therapy on the hypophyseal-adrenal system in bronchial asthma patients]. Ter Arkh. 1995;67(3):43-7. [PubMed:7770804]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 09:35